AstraZeneca Pharma India (AZPIL) has entered into a distribution services agreement with Sun Pharmaceutical Industries for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS).
AZPIL already has a brand under the trademark ‘Brilinta’, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.
Sun Pharma will be promoting and distributing ‘Axcer’ brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy.
